In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study
Purpose We sought to investigate the efficacy of in vitro extreme drug resistance (EDR) assay for the prediction of drug response, platinum-resistance (progression-free survival, PFS
Gespeichert in:
| Veröffentlicht in: | Journal of cancer research and clinical oncology 2009-11, Vol.135 (11), p.1513-1520 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1520 |
|---|---|
| container_issue | 11 |
| container_start_page | 1513 |
| container_title | Journal of cancer research and clinical oncology |
| container_volume | 135 |
| creator | Kim, Hee Seung Kim, Tae Joong Chung, Hyun Hoon Kim, Jae Weon Kim, Byung Gie Park, Noh Hyun Song, Yong Sang Bae, Duk Soo Kang, Soon Beom |
| description | Purpose
We sought to investigate the efficacy of in vitro extreme drug resistance (EDR) assay for the prediction of drug response, platinum-resistance (progression-free survival, PFS |
| doi_str_mv | 10.1007/s00432-009-0598-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67657654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1865613681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-45fc5db93c30dc4d92eb6aa69181184eb4bb37ddc3ce674427c84256078256323</originalsourceid><addsrcrecordid>eNp1kdtqFTEUhoModrf6AN5IEOzdaI4zE-9K8VAoeKPXIZNk2pSZZEwym-438jFdw95YEISQkJXvX4f8CL2h5AMlpPtYCBGcNYSohkjVN-QZ2tEtQjmXz9GO0I42ktH2DJ2X8kDgLjv2Ep1RJYQirNuh3zcR70PNCfvHmv3sscvrHc6-hFJNtB6bUswB14SreTTRF5wyXiZTQ1xnbNO8pDW6gkcI13uPl-xdsDWkiNOI7RRisGbCaa3AgjpE7JcA5BS28N7kYCK2W6n8CRvQp7J4SLD3kP0-5YpLXd3hFXoxmqn416fzAv388vnH9bfm9vvXm-ur28ZypWoj5GilGxS3nDgrnGJ-aI1pFe0p7YUfxDDwzjnLrW87IVhne8FkS7oeds74Bbo85oVGfq2-VD2HYv00wexpLbrtWglLAPjuH_AhrTlCb5oxIqWkTAJEj5CFsUr2o15ymE0-aEr05qE-eqjBQ715qAlo3p4Sr8Ps3ZPiZBoA70-AKfC3Y4bPC-Uvx6iSSrQUOHbkCjzFO5-fOvx_9T8pgbct</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220555125</pqid></control><display><type>article</type><title>In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kim, Hee Seung ; Kim, Tae Joong ; Chung, Hyun Hoon ; Kim, Jae Weon ; Kim, Byung Gie ; Park, Noh Hyun ; Song, Yong Sang ; Bae, Duk Soo ; Kang, Soon Beom</creator><creatorcontrib>Kim, Hee Seung ; Kim, Tae Joong ; Chung, Hyun Hoon ; Kim, Jae Weon ; Kim, Byung Gie ; Park, Noh Hyun ; Song, Yong Sang ; Bae, Duk Soo ; Kang, Soon Beom</creatorcontrib><description>Purpose
We sought to investigate the efficacy of in vitro extreme drug resistance (EDR) assay for the prediction of drug response, platinum-resistance (progression-free survival, PFS <6 months) and survival in patients with epithelial ovarian cancer (EOC) who received taxane- and platinum-based chemotherapy after surgery.
Methods
Between December 2005 and August 2007, 43 patients were enrolled prospectively. They underwent staging laparotomy followed by six or nine cycles of taxane- and platinum-based chemotherapy, and their tumors were submitted for in vitro EDR assay to taxanes (paclitaxel or docetaxel) and platinum compounds (carboplatin or cisplatin).
Results
The rates of EDR to taxanes and platinum compounds were 20.9% (9/43) and 23.3% (10/43). Patients with EDR to platinum compounds showed a lower rate of overall response (60 vs. 100%), a higher rate of platinum-resistance (50 vs. 18.2%) and poor overall survival (OS) (median OS; 29.2 vs. 33.7 months) than those without EDR to platinum compounds (
P
< 0.05), whereas patients with EDR to taxanes showed poor PFS than those without EDR to taxanes (12.5 vs. 19 months,
P
< 0.01). Moreover, suboptimal debulking surgery and EDR to taxanes were poor prognostic factors for PFS (adjusted hazard ratio 3.215 and 3.984; 95% confidence interval 1.845–7.895 and 3.814–11.674, respectively) although there was no independent risk factor for poor OS by the multivariate Cox’s proportional hazard analysis.
Conclusions
In vitro EDR assay to taxanes and platinum compounds may be helpful for predicting drug response, platinum-resistance and survival in patients with EOC who received taxane- and platinum-based chemotherapy after staging laparotomy.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-009-0598-0</identifier><identifier>PMID: 19449027</identifier><identifier>CODEN: JCROD7</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Cancer Research ; Carboplatin - therapeutic use ; Cell culture ; Chemotherapy ; Cisplatin - therapeutic use ; Clinical outcomes ; Cohort Studies ; Drug resistance ; Drug Resistance, Neoplasm ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Hematology ; Humans ; Internal Medicine ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasms, Glandular and Epithelial - drug therapy ; Neoplasms, Glandular and Epithelial - mortality ; Oncology ; Original Paper ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - mortality ; Pharmacology ; Pharmacology. Drug treatments ; Prospective Studies ; Taxoids - therapeutic use ; Tumors</subject><ispartof>Journal of cancer research and clinical oncology, 2009-11, Vol.135 (11), p.1513-1520</ispartof><rights>Springer-Verlag 2009</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-45fc5db93c30dc4d92eb6aa69181184eb4bb37ddc3ce674427c84256078256323</citedby><cites>FETCH-LOGICAL-c399t-45fc5db93c30dc4d92eb6aa69181184eb4bb37ddc3ce674427c84256078256323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-009-0598-0$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-009-0598-0$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21959461$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19449027$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Hee Seung</creatorcontrib><creatorcontrib>Kim, Tae Joong</creatorcontrib><creatorcontrib>Chung, Hyun Hoon</creatorcontrib><creatorcontrib>Kim, Jae Weon</creatorcontrib><creatorcontrib>Kim, Byung Gie</creatorcontrib><creatorcontrib>Park, Noh Hyun</creatorcontrib><creatorcontrib>Song, Yong Sang</creatorcontrib><creatorcontrib>Bae, Duk Soo</creatorcontrib><creatorcontrib>Kang, Soon Beom</creatorcontrib><title>In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Purpose
We sought to investigate the efficacy of in vitro extreme drug resistance (EDR) assay for the prediction of drug response, platinum-resistance (progression-free survival, PFS <6 months) and survival in patients with epithelial ovarian cancer (EOC) who received taxane- and platinum-based chemotherapy after surgery.
Methods
Between December 2005 and August 2007, 43 patients were enrolled prospectively. They underwent staging laparotomy followed by six or nine cycles of taxane- and platinum-based chemotherapy, and their tumors were submitted for in vitro EDR assay to taxanes (paclitaxel or docetaxel) and platinum compounds (carboplatin or cisplatin).
Results
The rates of EDR to taxanes and platinum compounds were 20.9% (9/43) and 23.3% (10/43). Patients with EDR to platinum compounds showed a lower rate of overall response (60 vs. 100%), a higher rate of platinum-resistance (50 vs. 18.2%) and poor overall survival (OS) (median OS; 29.2 vs. 33.7 months) than those without EDR to platinum compounds (
P
< 0.05), whereas patients with EDR to taxanes showed poor PFS than those without EDR to taxanes (12.5 vs. 19 months,
P
< 0.01). Moreover, suboptimal debulking surgery and EDR to taxanes were poor prognostic factors for PFS (adjusted hazard ratio 3.215 and 3.984; 95% confidence interval 1.845–7.895 and 3.814–11.674, respectively) although there was no independent risk factor for poor OS by the multivariate Cox’s proportional hazard analysis.
Conclusions
In vitro EDR assay to taxanes and platinum compounds may be helpful for predicting drug response, platinum-resistance and survival in patients with EOC who received taxane- and platinum-based chemotherapy after staging laparotomy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Carboplatin - therapeutic use</subject><subject>Cell culture</subject><subject>Chemotherapy</subject><subject>Cisplatin - therapeutic use</subject><subject>Clinical outcomes</subject><subject>Cohort Studies</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasms, Glandular and Epithelial - drug therapy</subject><subject>Neoplasms, Glandular and Epithelial - mortality</subject><subject>Oncology</subject><subject>Original Paper</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Pharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Taxoids - therapeutic use</subject><subject>Tumors</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kdtqFTEUhoModrf6AN5IEOzdaI4zE-9K8VAoeKPXIZNk2pSZZEwym-438jFdw95YEISQkJXvX4f8CL2h5AMlpPtYCBGcNYSohkjVN-QZ2tEtQjmXz9GO0I42ktH2DJ2X8kDgLjv2Ep1RJYQirNuh3zcR70PNCfvHmv3sscvrHc6-hFJNtB6bUswB14SreTTRF5wyXiZTQ1xnbNO8pDW6gkcI13uPl-xdsDWkiNOI7RRisGbCaa3AgjpE7JcA5BS28N7kYCK2W6n8CRvQp7J4SLD3kP0-5YpLXd3hFXoxmqn416fzAv388vnH9bfm9vvXm-ur28ZypWoj5GilGxS3nDgrnGJ-aI1pFe0p7YUfxDDwzjnLrW87IVhne8FkS7oeds74Bbo85oVGfq2-VD2HYv00wexpLbrtWglLAPjuH_AhrTlCb5oxIqWkTAJEj5CFsUr2o15ymE0-aEr05qE-eqjBQ715qAlo3p4Sr8Ps3ZPiZBoA70-AKfC3Y4bPC-Uvx6iSSrQUOHbkCjzFO5-fOvx_9T8pgbct</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Kim, Hee Seung</creator><creator>Kim, Tae Joong</creator><creator>Chung, Hyun Hoon</creator><creator>Kim, Jae Weon</creator><creator>Kim, Byung Gie</creator><creator>Park, Noh Hyun</creator><creator>Song, Yong Sang</creator><creator>Bae, Duk Soo</creator><creator>Kang, Soon Beom</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study</title><author>Kim, Hee Seung ; Kim, Tae Joong ; Chung, Hyun Hoon ; Kim, Jae Weon ; Kim, Byung Gie ; Park, Noh Hyun ; Song, Yong Sang ; Bae, Duk Soo ; Kang, Soon Beom</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-45fc5db93c30dc4d92eb6aa69181184eb4bb37ddc3ce674427c84256078256323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Carboplatin - therapeutic use</topic><topic>Cell culture</topic><topic>Chemotherapy</topic><topic>Cisplatin - therapeutic use</topic><topic>Clinical outcomes</topic><topic>Cohort Studies</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasms, Glandular and Epithelial - drug therapy</topic><topic>Neoplasms, Glandular and Epithelial - mortality</topic><topic>Oncology</topic><topic>Original Paper</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Pharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Taxoids - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Hee Seung</creatorcontrib><creatorcontrib>Kim, Tae Joong</creatorcontrib><creatorcontrib>Chung, Hyun Hoon</creatorcontrib><creatorcontrib>Kim, Jae Weon</creatorcontrib><creatorcontrib>Kim, Byung Gie</creatorcontrib><creatorcontrib>Park, Noh Hyun</creatorcontrib><creatorcontrib>Song, Yong Sang</creatorcontrib><creatorcontrib>Bae, Duk Soo</creatorcontrib><creatorcontrib>Kang, Soon Beom</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Hee Seung</au><au>Kim, Tae Joong</au><au>Chung, Hyun Hoon</au><au>Kim, Jae Weon</au><au>Kim, Byung Gie</au><au>Park, Noh Hyun</au><au>Song, Yong Sang</au><au>Bae, Duk Soo</au><au>Kang, Soon Beom</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>135</volume><issue>11</issue><spage>1513</spage><epage>1520</epage><pages>1513-1520</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><coden>JCROD7</coden><abstract>Purpose
We sought to investigate the efficacy of in vitro extreme drug resistance (EDR) assay for the prediction of drug response, platinum-resistance (progression-free survival, PFS <6 months) and survival in patients with epithelial ovarian cancer (EOC) who received taxane- and platinum-based chemotherapy after surgery.
Methods
Between December 2005 and August 2007, 43 patients were enrolled prospectively. They underwent staging laparotomy followed by six or nine cycles of taxane- and platinum-based chemotherapy, and their tumors were submitted for in vitro EDR assay to taxanes (paclitaxel or docetaxel) and platinum compounds (carboplatin or cisplatin).
Results
The rates of EDR to taxanes and platinum compounds were 20.9% (9/43) and 23.3% (10/43). Patients with EDR to platinum compounds showed a lower rate of overall response (60 vs. 100%), a higher rate of platinum-resistance (50 vs. 18.2%) and poor overall survival (OS) (median OS; 29.2 vs. 33.7 months) than those without EDR to platinum compounds (
P
< 0.05), whereas patients with EDR to taxanes showed poor PFS than those without EDR to taxanes (12.5 vs. 19 months,
P
< 0.01). Moreover, suboptimal debulking surgery and EDR to taxanes were poor prognostic factors for PFS (adjusted hazard ratio 3.215 and 3.984; 95% confidence interval 1.845–7.895 and 3.814–11.674, respectively) although there was no independent risk factor for poor OS by the multivariate Cox’s proportional hazard analysis.
Conclusions
In vitro EDR assay to taxanes and platinum compounds may be helpful for predicting drug response, platinum-resistance and survival in patients with EOC who received taxane- and platinum-based chemotherapy after staging laparotomy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>19449027</pmid><doi>10.1007/s00432-009-0598-0</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0171-5216 |
| ispartof | Journal of cancer research and clinical oncology, 2009-11, Vol.135 (11), p.1513-1520 |
| issn | 0171-5216 1432-1335 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67657654 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Cancer Research Carboplatin - therapeutic use Cell culture Chemotherapy Cisplatin - therapeutic use Clinical outcomes Cohort Studies Drug resistance Drug Resistance, Neoplasm Female Female genital diseases Gynecology. Andrology. Obstetrics Hematology Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasms, Glandular and Epithelial - drug therapy Neoplasms, Glandular and Epithelial - mortality Oncology Original Paper Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Pharmacology Pharmacology. Drug treatments Prospective Studies Taxoids - therapeutic use Tumors |
| title | In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-31T16%3A25%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20extreme%20drug%20resistance%20assay%20to%20taxanes%20or%20platinum%20compounds%20for%20the%20prediction%20of%20clinical%20outcomes%20in%20epithelial%20ovarian%20cancer:%20a%20prospective%20cohort%20study&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=Kim,%20Hee%20Seung&rft.date=2009-11-01&rft.volume=135&rft.issue=11&rft.spage=1513&rft.epage=1520&rft.pages=1513-1520&rft.issn=0171-5216&rft.eissn=1432-1335&rft.coden=JCROD7&rft_id=info:doi/10.1007/s00432-009-0598-0&rft_dat=%3Cproquest_cross%3E1865613681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220555125&rft_id=info:pmid/19449027&rfr_iscdi=true |